share_log

PetVivo (OTCMKTS:PETV) Share Price Passes Above Fifty Day Moving Average of $1.99

PetVivo (OTCMKTS:PETV) Share Price Passes Above Fifty Day Moving Average of $1.99

PetVivo(OTCMKTS:PETV)股價突破50日移動均線1.99美元
Defense World ·  2022/08/16 03:41

PetVivo Holdings, Inc. (OTCMKTS:PETV – Get Rating) crossed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $1.99 and traded as high as $2.35. PetVivo shares last traded at $2.33, with a volume of 19,235 shares traded.

PetVivo Holdings,Inc.(OTCMKTS:PETV-GET評級)在週一的交易中突破了50日移動均線。該股的50日移動均線為1.99美元,交易價格高達2.35美元。PetVivo的股票最新報2.33美元,成交量為19,235股。

PetVivo Price Performance

PetVivo性價比

The stock has a market cap of $23.22 million, a price-to-earnings ratio of -3.10 and a beta of 1.96. The company has a current ratio of 4.15, a quick ratio of 4.00 and a debt-to-equity ratio of 0.01. The stock has a 50-day moving average price of $1.99 and a two-hundred day moving average price of $1.83.

該股市值為2322萬美元,市盈率為-3.10倍,貝塔係數為1.96。該公司的流動比率為4.15,速動比率為4.00,債務權益比率為0.01。該股的50日移動均線價格為1.99美元,200日移動均線價格為1.83美元。

Get
到達
PetVivo
PetVivo
alerts:
警報:

Institutional Investors Weigh In On PetVivo

機構投資者看好PetVivo

An institutional investor recently raised its position in PetVivo stock. Vanguard Group Inc. increased its position in shares of PetVivo Holdings, Inc. (OTCMKTS:PETV – Get Rating) by 5.2% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 226,137 shares of the company's stock after purchasing an additional 11,251 shares during the quarter. Vanguard Group Inc. owned approximately 2.31% of PetVivo worth $461,000 as of its most recent filing with the SEC. 13.70% of the stock is currently owned by hedge funds and other institutional investors.

一家機構投資者最近提高了對PetVivo股票的頭寸。根據先鋒集團向美國證券交易委員會披露的最新信息,今年第一季度,先鋒集團將PetVivo Holdings,Inc.的股票頭寸增加了5.2%。該機構投資者在本季度額外購買了11,251股後,持有226,137股該公司股票。截至最近向美國證券交易委員會提交的文件,先鋒集團持有PetVivo約2.31%的股份,價值46.1萬美元。13.70%的股票目前由對衝基金和其他機構投資者持有。

About PetVivo

關於PetVivo

(Get Rating)
(獲取評級)

PetVivo Holdings, Inc, a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses.

PetVivo控股公司是一家生物醫療設備公司,從事治療動物疾病和疾病的醫療設備和生物材料的製造、商業化和許可。它的主要產品是Spryng,一種由獸醫管理的關節內注射,用於治療跛行和其他關節疾病,如狗和馬的骨關節炎。

Featured Stories

專題報道

  • Get a free copy of the StockNews.com research report on PetVivo (PETV)
  • 3 Blowout Earnings Reports That Could Mark Turning Points
  • Will CrowdStrike Extend Its Streak Of Topping Earnings Views?
  • Skyworks Solutions Is Worth A Look At These Prices
  • 3 Stocks Set to Lead the Nasdaq Bull Market
  • MarketBeat Podcast: ESG – Profitably Invest Your Values
  • 免費獲取StockNews.com關於PetVivo的研究報告(PETV)
  • 3份井噴式收益報告可能標誌着轉折點
  • CrowdStrike是否會延續其盈利排行榜榜首的勢頭?
  • Skyworks Solutions值得看看這些價格
  • 3只股票將引領納斯達克牛市
  • MarketBeat播客:ESG--有利可圖地投資你的價值

Receive News & Ratings for PetVivo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetVivo and related companies with MarketBeat.com's FREE daily email newsletter.

接受PetVivo Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對PetVivo和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論